Diabetes PubMed

The current review of the published literature supports that insulin lispro is a safe alternative to human insulin with similar perinatal outcomes and potentially improved glycemic control in the management of diabetes in pregnancy.

The current clinical data do not allow the conclusion that treatment with insulin glargine is associated with increased cancer risk. On the other hand, prospective studies that exclude an impact on cancer risk in risk populations are currently not available.

Once-daily insulin detemir could be considered an effective therapy for people with type 2 diabetes on lifestyle interventions and oral anti-diabetic agent therapy who require insulin.

Introduction of insulin detemir, at the appropriate time, can help empower patients to reach glycaemic targets, with a reduced risk of hypoglycaemia and less weight gain.

...the major advantage of insulin Glargine remains the greater safety of a lower frequency of hypoglycemic reactions.

Glargine use during pregnancy from preconception through delivery, showed to be safe since it is associated with decreased maternal and neonatal adverse outcomes compared with NPH insulin-treated patients.

Combination therapy of once-daily insulin glargine versus three-times daily insulin lispro both with oral antidiabetic drugs (OADs), in the management of insulin-dependent type 2 diabetes offers the potential for substantial cost savings from the German statutory health insurance (SHI) perspective.

Based on the evidence from published clinical trials, insulin glargine appears to have equal clinical efficacy to NPH insulin, produces similar reductions in HbA(1c), and is associated with lower FPG and FBG levels and a consistent and significant reduction in the incidence of nocturnal hypoglycemia in patients with type 2 diabetes.

We conclude that insulin glargine provides a simple and effective option that is more satisfactory to patients than is lispro for early initiation of insulin therapy, since it was associated with a lower risk of hypoglycaemia, fewer injections, less blood glucose self monitoring, and greater patient satisfaction than was insulin lispro.

In a study in patients with type 2 diabetes, the overall postprandial blood glucose excursions were lower with insulin glulisine than with insulin lispro.

One unit of insulin glulisine has the same glucose-lowering effect as one unit of regular human insulin. Insulin glulisine has a favorable safety profile, which is not significantly different from that of regular human insulin.

Thus, insulin glulisine is an effective and well tolerated option for the treatment of patients with type 1 and type 2 diabetes.

Our findings suggest that lispro is likely to improve quality-adjusted life expectancy (QALE), reduce frequency of diabetes-related complications and lifetime medical costs compared with regular human insulin (RHI).

In this elderly subgroup post-hoc analysis, LM25 (lispro 25%/insulin lispro protamine suspension 75%) demonstrated a lower endpoint HbA(1c) and a higher % of patients reaching HbA(1c) target of < 7.0%, but with more weight gain and higher rates of hypoglycaemia compared to glargine.

In these randomised controlled diabetes trials, patients treated with insulin detemir had a lower or similar occurrence of a cancer diagnosis compared with patients treated with NPH insulin or insulin glargine, respectively.

Insulin detemir was associated with less hypoglycaemia than insulin glargine but not NPH insulin in relatively well-controlled people with Type 1 diabetes during and after exercise.

However, a better safety profile, disclosed by the lower incidence of nocturnal and severe hypoglycemia episodes, was observed for insulin glargine.

Twice-daily injections of biphasic insulin aspart 30 may be more suitable for obese patients whereas multiple injections of insulin aspart with or without NPH insulin may be preferable for those with a longer duration of diabetes.

Initiation of either NPH or glargine was associated with major cost reductions and infrequent hypoglycemia-related claims.

A comparison of the effects of human and animal insulin as well as of the adverse reaction profile did not show clinically relevant differences.